Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset TECH
Coverage 166,246 Raw stories ingested 21,838 rewritten in CS_CZ • 25 to rewrite (last 2 days).
Agents 7 Live Pipeline agents
  • FMP Stock News Fetch every minute 44s ago
  • FMP Forex News Fetch every 5 min 44s ago
  • CoinGecko News Fetch every 5 min 2m ago
  • FIO Stock News Fetch every 10 min 5m ago
  • Patria Stock News Fetch every 10 min 5m ago
  • Editorial rewrite Rewrite every minute running now
  • Asset sync Assets every 1 hour 44m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-09-01 11:43 8d ago
2026-09-01 06:30 8d ago
Bio-Techne získala validaci SBTi pro cíle snižování emisí
TECH Bio-Techne Corp
FMP Stock News 78
Original source text
Fiscal 2026 highlights:

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed , /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.

The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.

Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.

"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."

Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.

ABOUT BIO-TECHNE

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

CONTACT:

Corporate Communications
[email protected]

David Clair, Vice President
Investor Relations
[email protected]

SOURCE Bio-Techne Corporation
2026-08-31 05:17 9d ago
2026-08-27 01:01 13d ago
CMB.TECH ve 2. čtvrtletí vykázala čistý zisk i EBITDA
TECH Bio-Techne Corp
FMP Stock News 92
Original source text
ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2026.

HIGHLIGHTS

Financial highlights: Profit for the period of USD 364.4 million in Q2 2026. EBITDA for the same period was USD 552.8 million.CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 x 2-year CSOV time charters and 1 x 1-year VLCC time charter​Intention to distribute an amount of USD 0.64 per share.  Fleet highlights:

Delivery of 9 newbuilding vessels (Q2 + Q3 to date): Newcastlemaxes: Mineral Latvija, Mineral Magyar, Mineral Eesti, Mineral LietuvaVLCCs: MoriniSuezmaxes: Cap Grace, Cap JosephCSOV: Windcat HaarlemCTV: FRS Windcat 65  CMB.TECH and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-powered Newcastlemax vessels (210,000 dwt)Previously announced sale of VLCCs Ilma (2012, 314,000 dwt) and VLCC Ingrid (2012, 314,000 dwt). The sale generated a gain of a USD 98.2 million in Q2 2026.Previously announced sale of Suezmax Sienna (2007 - 150,205 dwt). The sale generated a gain of USD 29.2 million.Sale of VLCC Donoussa (2016, 299,999 dwt). This sale will generate a gain of approximately 74.3 million USD in Q4 2026, based on the net sale price and book values.Sale of three Suezmaxes, Brest (2023, 156,851 dwt), Brugge (2023, 156,851 dwt) and Bristol (2024, 156,851 dwt). These sales will generate a gain of approximately 100.2 million USD in Q3 2026 and 56.9 million USD in Q4 2026, based on the net sale price and book values. For the second quarter of 2026, the company realised a net profit of USD 364.4 million or USD 1.26 per share (second quarter 2025: a net profit of 7.8 USD million or USD 0.04 per share attributable to the owners of the Company). EBITDA (a non-IFRS measure) for the same period was USD 552.8 million (second quarter 2025: USD 224.1 million).

“CMB.TECH achieved excellent results in the second quarter of 2026, supported by continued strength in tanker and dry bulk markets. We continue to make hay while the sun shines, building on the important strategic decisions taken over the past three years: diversifying beyond tankers, acquiring Golden Ocean and investing in a future-proof newbuilding programme.

While uncertainties remain around global trade, geopolitical tensions and the tanker orderbook, CMB.TECH is well positioned to navigate changing market conditions and to continue creating long-term value.” - Alexander Saverys, CEO CMB.TECH.

Key figures

             The most important key figures (unaudited) are:                       (in thousands of USD)   Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025              Revenue          703,943         387,808         1,223,573         622,852          Other operating income          16,724         13,021         37,055         20,155                      Raw materials and consumables          (594)         (2,319)         (2,003)         (5,128)          Voyage expenses and commissions          (144,349)         (81,338)         (249,168)         (123,742)          Vessel operating expenses          (125,469)         (113,644)         (252,956)         (175,473)          Charter hire expenses          (3,756)         (1,307)         (3,974)         (1,620)          General and administrative expenses          (30,771)         (33,548)         (58,558)         (56,395)          Net gain (loss) on disposal of tangible assets          127,517         57,340         394,871         103,791          Depreciation and amortisation          (111,425)         (108,698)         (217,996)         (164,369)          Impairment reversals/(losses)          140         (3,573)         729         (3,573)                      Net finance expenses          (76,172)         (118,225)         (157,869)         (182,440)          Share of profit (loss) of equity accounted investees          9,399         1,622         21,495         1,571          Profit (loss) before income tax          365,187         (2,861)         735,199         35,629                      Income tax benefit (expense)          (807)         (4,723)         (1,985)         (2,840)  Profit (loss) for the period          364,380         (7,584)         733,214         32,789                      Attributable to:            Owners of the Company          364,380         7,768         733,214         51,766           Non-controlling interest          —         (15,352)         —         (18,977)                                             Earnings per share:                     (in USD per share) Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025             Weighted average number of shares (basic) *         290,169,769         194,216,835                 290,169,769         194,216,835          Basic earnings per share         1.26         0.04                 2.53         0.27                                The number of shares issued on 30 June 2026 is 315,977,647. However, the number of shares excluding the owned shares held by CMB.TECH at 30 June 2026 is 290,169,769.             EBITDA reconciliation (unaudited):                     (in thousands of USD) Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025             Profit (loss) for the period         364,380         (7,584)                 733,214         32,789          + Net finance expenses         76,172         118,225                 157,869         182,440          + Depreciation and amortisation         111,425         108,698                 217,996         164,369          + Income tax expense (benefit)         807         4,723                 1,985         2,840          EBITDA (unaudited)         552,784         224,062                 1,111,064         382,438                                 EBITDA per share:                       (in USD per share)  Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025              Weighted average number of shares (basic)          290,169,769         194,216,835                 290,169,769         194,216,835          EBITDA          1.91         1.15                 3.83         1.97                                  All figures, except for EBITDA and EBITDA per share, have been prepared under IFRS as adopted by the EU (International Financial Reporting Standards) and have not been audited nor reviewed by the statutory auditor.

Intention of distribution

The Supervisory Board proposes a total distribution of USD 0.64 per share, consisting of (i) an intermediary dividend of USD 0.21 per share (subject to 30% withholding tax, to the extent no exemption or reduction applies) and (ii) a payment of USD 0.43 per share out of the available share premium (which is exempt from withholding tax) (the “Distribution”). 

The Distribution is subject to the completion of the relevant corporate procedures prescribed by the Belgian Companies and Associations Code (Wetboek van vennootschappen en verenigingen / Code des sociétés et des associations) and, in particular, the approval of the Distribution by the Special Shareholders’ Meeting of CMB.TECH, which will be convened later this year (the “Shareholders’ Meeting”). 

CMB.TECH will provide further information on the payment date (expected in October), record date and other practical modalities of the Distribution once the Distribution is effectively approved by the Shareholders Meeting, in accordance with applicable regulations. 

TCE

The average daily time charter equivalent rates (TCE, a non IFRS-measure) can be summarised as follows:

 Q2 2026Q2 2025Quarter-to-Date Q3 2026USD/dayUSD/dayUSD/dayFixed %DRY BULK VESSELSNewcastlemax average spot rate(1)46,19823,08143,09685%Capesize average spot rate(1)39,998 32,87377%Capesize average time charter rate32,102   Panamax/Kamsarmax average spot rate(1)20,226 19,13784%Panamax/Kamsarmax average time charter rate13,765   TANKERSVLCC average spot rate (1)126,79044,981125,40483%VLCC average time charter rate(3)78,43446,094  Suezmax average spot rate(1) (3)123,40540,160117,57973%Suezmax average time charter rate34,72633,023  CONTAINER VESSELSAverage time charter rate29,58929,378  CHEMICAL TANKERSAverage spot rate(1) (2)22,02122,41122,350NAAverage time charter rate19,65819,306  OFFSHORE ENERGYCSOV Average time charter rate64,451 50,51165%CTV Average time charter rate3,5653,1463,76598% 1) Reporting load-to-discharge for TCEs, in line with IFRS 15, net of commission. Revenue days are the aggregate number of calendar days in the period in which the vessels are owned by the Company or chartered by the Company less days on which a vessel is off hire or repositioning days in connection with sale
(2) CMB.TECH owned ships in Stolt Pool (excluding technical off hire days)
(3) Including profit share where applicable

CMB.TECH FLEET DEVELOPMENTS

Commercial contracts

CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 x 2-year CSOV time charters and 1 x 1-year VLCC time charter​CMB.TECH and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-powered Newcastlemax vessels (210,000 dwt) Sales

Following vessels were delivered to their new owners in Q2 2026 - generating a total gain of approximately USD 127.4 million:

Two VLCCs: Ilma (2012, 314,000 dwt) and Ingrid (2012, 314,000 dwt) - gain of approximately USD 98.2 million in Q2 2026, based on the net sales price and book values. One Suezmax Sienna (2007, 150,205 dwt). The sale generated a gain of USD 29.2 million and was delivered in the second quarter of 2026. Following vessels will be delivered to their new owners in Q3 2026:

Two Suezmaxes: Brest (2023, 156,851 dwt) and Brugge (2023, 156,851 dwt). This sale will generate a gain of approximately 100.2 million USD in Q3 2026, based on the net sale price and book values. Following vessels will be delivered to their new owners in Q4 2026:

VLCC Donoussa (2016, 299,999 dwt). This sale will generate a gain of approximately 74.3 million USD in Q4 2026, based on the net sale price and book values.Suezmax Bristol (2024, 156,851 dwt). This sale will generate a gain of approximately 56.9 million USD in Q4 2026​, based on the net sale price and book values. Newbuilding deliveries

Delivery dateType of vesselName8 April 2026SuezmaxCap Grace (2026, 156,000 dwt)27 April 2026SuezmaxCap Joseph (2026, 156,000 dwt)4 May 2026CSOVWindcat Haarlem (2026)11 May 2026NewcastlemaxMineral Latvija (2026, 210,000 dwt)28 May 2026NewcastlemaxMineral Eesti (2026, 210,000 dwt)8 June 2026NewcastlemaxMineral Magyar (2026, 210,000 dwt)10 June 2026VLCCMorini (2026, 319,000 dwt)29 June 2026NewcastlemaxMineral Lietuva (2026, 210,000 dwt)14 July 2026CTVFRS Windcat 65 MARKET & OUTLOOK

Bocimar – Dry Bulk Market1

Dry bulk markets entered 2026 with strong momentum, with the Baltic Dry Index averaging materially higher year-on-year in Q2 and spot earnings across major dry-bulk vessel classes trending well above seasonal norms. Capesize C5TC (BCI-182) time charter equivalent (TCE) earnings averaged USD 39,806 per day during Q2 2026, compared to a 10-year historical average of USD 22,926 per day2. Average sector earnings in the second quarter were supported by robust major bulk volumes, firm minor bulk activity, and generally tighter effective fleet supply. Continuing on a strong Q2, the Capesize C5TC (BCI-182) average for July stands at 38,646 USD/day, 13,671 USD/day higher compared to July 2025 (BCI-182 recalculated basis) – and increased further in August up to 46,201 USD/day.

Iron ore trade remained a key pillar of dry bulk demand during the second quarter of 2026. Overall global iron ore seaborne transportation increased by 0.9% between Q2 2025 and Q2 2026, and by 12.2% between Q1 2026 and Q2 2026. China imported 316.4 million tonnes of iron ore in Q2, up 0.6% year-on-year, bringing first-half imports to 637.4 million tonnes, an increase of 5.1% compared to the same period last year. Although Chinese steel production remains under pressure, domestic iron ore production declined by 7% year-on-year to 466.9 million tonnes during the first half of the year, increasing reliance on higher-quality imported ores.

Looking ahead, continued strength in seaborne iron ore trade is supported by the production and shipment guidance of the major iron ore miners and the ongoing ramp-up of the Simandou project. Iron ore export volumes historically strengthen in the second half of the year, with weekly shipments typically increasing by approximately 7.7% from week 27 (start H2) through year-end compared with the first H1 weeks. Vale maintained its 2026 production guidance of 335-345 million tonnes, implying second-half production growth ranging from -2.0% to +3.4% year-on-year depending on the outcome within the guidance range. Fortescue's FY27 shipment guidance of 197-207 million tonnes points to broadly stable export volumes, while BHP's FY27 production guidance midpoint of 266 million tonnes is also broadly unchanged year-on-year. Rio Tinto's unchanged 2026 guidance implies a meaningful increase in second-half Pilbara shipments compared with the first half, while the gradual ramp-up of Simandou provides additional support to tonne-mile demand. Although initial Simandou volumes remain modest, the Guinea-China trade route is more than three times longer than the traditional Australia-China iron ore trade, creating a disproportionately positive impact on vessel demand and fleet utilisation.

Coal emerged as one of the strongest contributors to dry bulk demand during the quarter. Global seaborne coal transportation reached 276 million tonnes in Q2 2026, increasing by 11.8% between Q2 2025 and Q2 2026, and by 15.1% between Q1 2026 and Q2 2026. Seaborne coal transportation accelerated following the disruption of Middle East energy flows, as higher LNG prices supported coal consumption in several importing countries (mainly Europe, Japan, South Korea, and Taiwan). While coal demand remains closely linked to weather patterns and energy markets, current market fundamentals suggest continued support for seaborne coal demand through Q3 and potentially into Q4.

In addition, Chinese domestic coal production was constrained by enhanced safety inspections following a major mining accident, while rising summer temperatures and strong power demand increased import requirements. China’s electricity consumption rose 5.3% year-on-year during the first half of 2026, with repeated records in peak electricity loads. Demand for both thermal and metallurgical coal strengthened, with Australian coal shipments to China nearing multi-year highs in July 2026.

Bauxite continues to be one of the strongest growth commodities in the dry bulk market. Despite recurring rumours regarding export restrictions in Guinea, volumes have remained robust and largely uninterrupted. Global seaborne bauxite transportation reached 60.6 million tonnes in Q2 2026, increasing by 4.6% between Q2 2025 and Q2 2026, and decreasing -13.9% between Q1 2026 and Q2 2026. As per the regular seasonal pattern, volumes eased during the peak rainy season (summer period). Volumes are expected to recover as weather conditions improve by Q3/Q4. As a result, bauxite is expected to remain an important source of tonne-mile demand during the second half of the year and continues to play an increasingly important role in global dry bulk trade growth.

Grain trade also provided solid support to dry bulk markets during the quarter. Global seaborne grains transportation reached 70.0 million tonnes in Q2 2026, increasing by 8.6% between Q2 2025 and Q2 2026, and by 0.7% between Q1 2026 and Q2 2026. Brazil remained the dominant supplier (128 million tonnes for H1 or 27.8% market share), benefiting from a large crop and competitive pricing, while the United States (87 million tonnes for H1 or 18.9% market share) has gradually regained market share and is expected to increase exports during the upcoming harvest season. The competition between Brazilian and US exports to China is supportive for tonne-mile demand and is expected to sustain healthy vessel utilisation during the second half of 2026 as seasonal trade flows shift between origins.

Weather developments remain an important factor for dry bulk markets. The National Oceanic and Atmospheric Administration (NOAA) officially declared El Niño in June 2026, with a 97% chance it will persist through early spring 2027. Historically, major El Niño events have disrupted agricultural production, altered commodity trade patterns, affected hydropower generation and increased coal demand in several regions. Early impacts have already been observed in Asia through stronger electricity demand and changing energy consumption patterns. While full weather effects always remain uncertain, a prolonged and severe El Niño event could support additional commodity trade flows and increase volatility across several dry bulk cargo segments through late 2026 and into 2027.

There have been some reports about a pick-up in demand for coal-fired power generation in Japan and the need to replace the drop in hydro generation as 2Q26 El Niño weather patterns pressured hydropower output. This is happening on the backdrop of reduced gas-fired output on gas-to-coal switching as the Hormuz conflict continues to keep LNG prices high. Coal discharges to Japan have been up 4% year-over-year, with thermal coal discharges increasing to 53.9 million tonnes in H1 2026, whilst coking coal discharges remained largely flat.

Bocimar has 40 (+6NB) Newcastlemaxes on the water (average age 3.2y), 37 Capesize vessels on the water (average age 11.2y), and 30 Kamsarmax/Panamax vessels on the water (average age 7.4y).

Bocimar performance highlights:

 TCE Q2 2026QTD Q3 2026Newcastlemax SPOT46,19843,096 (85% fixed)Capesize SPOT39,99832,873 (77% fixed)Kamsarmax/Panamax SPOT20,22619,137 (84% fixed) Euronav – Tanker Markets3

Crude tanker markets experienced exceptional volatility during Q2 2026, primarily driven by escalating geopolitical tensions in the Middle East and the disruption of shipping flows through the Strait of Hormuz (SOH) and the Bab el-Mandeb Strait. Transit volumes through the Strait of Hormuz declined materially beginning of March from on average 120 daily crossing to on average 10 daily crossings between March and mid-June. On 17 June, the presidents of the US and Iran signed the Islamabad Memorandum, that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal, enabling a temporary ceasefire. This resulted in a rapid recovery of Strait of Hormuz traffic with on average more than 40 daily SOH crossing. Geopolitical tensions escalated again in early July, and the ceasefire ended on July 7th. As a resultant, daily crossing dropped again towards on average 20 daily crossings. Both sides have since treated the Islamabad MoU as void, the US blockade is reported as still operating, Bab el-Mandeb transits have fallen to multi-month lows on renewed Houthi activity – increasing the likelihood of Red Sea escalation risk.

The resulting scramble for available tonnage led to sharp spikes in spot freight rates across key benchmark routes. Against this backdrop, VLCC time charter equivalent (TCE) earnings averaged USD 140,029 per day in Q2 2026, compared to a Q2 10-year historical average of USD 30,198 per day. Suezmax earnings followed a similar trajectory, with Q2 2026 TCE averaging USD 146,567 per day versus a Q2 10-year average of USD 30,946 per day.

The disruption also led to a widespread reconfiguration of global crude trade flows. Importing nations increasingly sourced barrels from alternative regions, while exporters outside the Middle East, including the United States, Brazil, Kazakhstan and Venezuela, increased shipments to partially offset lost Arabian Gulf volumes. Longer voyage distances and a more complex trading environment temporarily supported tonne-mile demand and fleet utilisation. At the same time, elevated uncertainty around regional security conditions delayed a full return to normal trading patterns and encouraged charterers to secure tonnage well in advance. However, despite the strong freight market performance, several underlying market indicators suggest a more cautious medium-term outlook.

During the recent disruption around the Strait of Hormuz, Chinese crude imports declined sharply, as buyers drew on substantial inventories rather than competing aggressively for replacement barrels. China’s strategic and commercial crude inventories were estimated at around 1.25 billion barrels at the end of 2025, providing a significant buffer against supply shocks and elevated prices. This inventory position enables China to be a price-sensitive and tactical buyer of seaborne crude oil. Rather than acting as a passive source of demand, China can increasingly time purchases depending on price levels, refinery margins and geopolitical risk. This helped cushion the immediate impact of the Iran-related disruption on global oil prices, but it also makes future crude import demand more dependent on inventory cycles and opportunistic restocking. For crude tanker demand, the medium-term outlook therefore depends not only on underlying oil consumption, but also on the pace at which China rebuilds inventories. Once the oil prices settle again, restocking in China (and other Asian economies) could support seaborne crude flows and tonne-mile demand. At the same time, Chinese refiners remain cautious amid weakened domestic fuel demand, high product inventories and continued fuel substitution through continuously increasing electrification and growth in the renewables sector, and by oil to coal switching. China’s high EV penetration has allowed some switching to driving on electricity rather than gasoline: gasoline consumption was 23% lower and EV charging volume 60% higher year over year in April and May.

Despite recent geopolitical disruptions, the underlying global oil market continues to face the prospect of a significant supply surplus. To date, there has been no sustained damage to major energy production infrastructure, supporting expectations that global oil supply can recover relatively quickly once tensions ease. In such a scenario, depleted inventories would likely be replenished, and trade flows progressively normalise. While recent events have temporarily supported tanker demand through longer haul voyages, market fundamentals suggest that any prolonged normalisation of Middle-East trade flows could see tanker demand gradually return towards underlying historic levels. Looking ahead, the ever-growing crude tanker orderbook remains an important consideration for the medium-term market balance and earnings outlook. Over the past months, the orderbook experienced the strongest period of newbuilding investment in the last 50 years (620 VLCCs and Suezmax units on order).

Euronav has 2 FSOs (average age 24y), 4 (+1NB) VLCCs (average age <1.0y) and 15 Suezmaxes (average age 8.1y) on the water4.

Euronav performance highlights:

 TCE Q2 2026QTD Q3 2026VLCC SPOT126,790 USD/day125,404 (83% fixed)SUEZMAX SPOT123,405 USD/day117,579 (73% fixed)  Delphis – Container Markets5

Container markets strengthened during the second quarter of 2026, supported by resilient cargo demand, continued disruption in Middle Eastern trade lanes and elevated congestion across key transhipment hubs. The closure of the Strait of Hormuz and the delayed return of Red Sea transits extended voyage distances, tightened effective vessel supply and supported both freight and charter markets. As a result, time charter rates reached their highest levels outside the post-pandemic period, while freight rates increased materially throughout the quarter, particularly on the Asia-Europe and Transpacific trades. Global trade volumes remained resilient despite regional disruptions, supported by robust demand on the main East-West routes, Intra-Asia and North-South trades.

Peak season demand, ongoing supply chain adjustments and a gradual rather than immediate normalisation of Middle East trade flows are expected to support freight and charter markets during the remainder of the summer period. On the other side, China's official manufacturing PMI fell to 49.2 in July (from 50.3), returning to contraction after four months of expansion. The deterioration in both domestic and export demand points to softer demand for containerised imports of raw materials and intermediate goods, as well as slower growth in container exports in the coming months. If export demand continues to weaken, container shipping volumes on the major Asia–Europe and Transpacific trade lanes are likely to come under pressure.

While global container trade is still expected to continue growing during 2026 (+3.0% year-on-year in billion TEU-miles), fleet growth is forecast to exceed demand growth, supported by a historically large orderbook representing approximately 38% of the existing fleet. In addition, any eventual normalisation of Red Sea routing would reduce tonne-mile demand and increase effective vessel supply – meaning that for 2027, container demand is forecast to decrease by -5.8% in billion TEU-miles.

Delphis has 4 x 6,000 TEU (average age 1.8y) on the water and 1 NB 1,400 TEU container vessel. All vessels are employed under 10 to 15-year time charter contracts.

Bochem – Chemical Markets6

Chemical tanker markets remained relatively resilient during the second quarter of 2026 despite significant disruption to global trade flows following the closure of the Strait of Hormuz. While chemical trade volumes temporarily declined and tanker transits through the region fell sharply, freight markets benefited from vessel dislocations, supply chain reconfiguration and longer voyage distances on selected routes. Spot freight rates remained above pre-conflict levels, supported by strong export activity from both the United States and Asia. US producers continued to benefit from a feedstock cost advantage, increasing exports to Europe, Latin America and Asia, while Chinese exporters leveraged strong inventories and feedstock flexibility to maintain robust regional trade flows.

As the quarter progressed, market participants adapted to the new operating environment, with chemical cargoes increasingly rerouted between regions. Demand for aromatics and petrochemical feedstocks remained broadly healthy, supported by inventory replenishment and shifting sourcing patterns. These developments generated additional tonne-mile demand on several long-haul corridors, partly offsetting reduced activity in the Middle East. At the same time, firm conditions in adjacent product tanker markets helped support vessel utilisation across the chemical tanker sector.

Looking ahead, the market outlook for the second half of 2026 remains constructive but subject to elevated uncertainty. The gradual normalisation of Hormuz transits should support a recovery in trade activity, although chemical cargo flows may take longer than crude oil and refined products to return to historical patterns. Furthermore, the sector faces a sizeable orderbook, with a meaningful number of chemical and product tanker deliveries scheduled through 2026-2028. While expected growth in seaborne chemical trade should absorb part of this additional capacity, the pace of demand recovery and vessel deliveries will be key determinants of freight market performance.

Bochem’s chemical tanker fleet comprises out of 8 delivered vessels, and 8 NB vessels (average age <1y). They are employed under a 10-year time charter (8 vessels), under a 7-year time charter (6 vessels), and in a spot pool (2 vessels).

Bochem performance highlights:

 TCE Q2 2026QTD Q3 202625k DWT stainless Steel (Pool)22,021 USD/day22,350 Windcat – Offshore Energy Markets7

The offshore energy market remained robust during the second quarter of 2026 despite a challenging investment backdrop for the wider offshore wind industry. While project sanctioning activity remained subdued, with only limited new final investment decisions recorded during the period, offshore wind construction, commissioning and operations & maintenance activity continued at high levels across Europe and Asia. A near-record pipeline of projects under construction supported strong demand for both CSOVs and CTVs, resulting in high utilisation and healthy chartering activity.

The European CSOV market remained particularly strong throughout the quarter. High fleet utilisation, limited prompt vessel availability and continued demand from offshore wind installation and maintenance campaigns supported attractive charter rates. Premium CSOVs were largely committed through the summer season, with charter rates typically ranging between EUR 50,000 and EUR 75,000 per day. Demand broadened beyond offshore wind as oil and gas operators increasingly adopted walk-to-work solutions for offshore maintenance activities. This growing crossover demand helped absorb additional capacity entering the market and further strengthened utilisation levels. European Tier-1 CSOV utilisation remained close to full employment, while average charter rates increased year-on-year. Looking ahead to the second half of 2026, market fundamentals remain supportive. Offshore wind construction activity across Europe, particularly in the Baltic Sea and North Sea, is expected to sustain strong demand for offshore support vessels, while emerging opportunities in the oil and gas sector provide an additional source of employment for CSOVs. However, visibility beyond 2026 remains more balanced with the rapid CSOV fleet expansion.

The CTV market also delivered solid performance during the quarter. Vessel availability tightened significantly ahead of the summer maintenance season, with most vessels fixed on contracts and only limited spot capacity available. Strong utilisation across Northwest Europe supported stable charter rates at historically attractive levels. Continued growth in offshore wind operational capacity and increasing maintenance requirements provided a supportive backdrop for vessel demand, while newbuild ordering activity remained disciplined.

Windcat has 3 (+4NB) CSOVs (average age <1y), and 60 (+3NB) CTVs (average age 10.4y).

Windcat performance highlights:

 TCE Q2 2026QTD Q3 2026CSOV 64,45150,511 (65% fixed)CTV3,5653,765 (98% fixed) CONFERENCE CALL
The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information Event Type: Video conference call with slide presentationEvent Date:27 August 2026Event Time:8 a.m. EST / 2 p.m. CETEvent Title: “Q2 2026 Earnings Conference Call”Event Site/URL:  https://events.teams.microsoft.com/event/9fcf4513-4ad3-44ec-8908-7058dfe26b88@d0b2b045-83aa-4027-8cf2-ea360b91d5e4 To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 244 207 376#

Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

Publication Q3 2026 results – 26 November 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.

Condensed consolidated interim statement of financial position (unaudited)

(in thousands of USD)

          June 30, 2026  December 31, 2025ASSETS             Non-current assets      Vessels          6,875,419  6,323,773Assets under construction          532,660  739,373Right-of-use assets          4,935  4,847Other tangible assets          48,002  23,981Intangible assets          16,055  12,710Goodwill          177,022  177,022Receivables          98,018  97,116Investments          154,217  111,346Deferred tax assets          2,541  2,850       Total non-current assets  7,908,869  7,493,018       Current assets      Inventory          120,674  77,175Trade and other receivables          415,688  320,843Current tax assets          2,828  4,912Short-term investments          8,271  —Cash and cash equivalents          151,574  146,529   699,035  549,459       Non-current assets held for sale          219,985  363,097       Total current assets  919,020  912,556       TOTAL ASSETS  8,827,889  8,405,574              EQUITY and LIABILITIES             Equity      Share capital          343,440  343,440Share premium          1,689,882  1,817,557Translation reserve          5,146  9,502Hedging reserve          1,044  90Treasury shares          (284,508)  (284,508)Retained earnings          1,365,990  737,239       Equity attributable to owners of the Company  3,120,994  2,623,320       Non-current liabilities      Bank loans          2,869,323  2,839,590Other borrowings          1,998,055  1,876,795Lease liabilities          4,014  3,368Other payables          15,072  20Employee benefits          1,176  1,180Deferred tax liabilities          26  485       Total non-current liabilities  4,887,666  4,721,438       Current liabilities      Trade and other payables          235,139  222,492Current tax liabilities          2,807  8,288Bank loans          195,082  351,170Other notes          203,619  203,287Other borrowings          180,981  273,898Lease liabilities          1,587  1,681Provisions          14  —       Total current liabilities  819,229  1,060,816       TOTAL EQUITY and LIABILITIES  8,827,889  8,405,574               Condensed consolidated interim statement of profit or loss (unaudited)

(in thousands of USD except per share amounts)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025Shipping income      Revenue  1,223,573  622,852Gains on disposal of vessels/other tangible assets  394,871  103,791Other operating income  37,055  20,155Total shipping income  1,655,499  746,798       Operating expenses      Raw materials and consumables          (2,003)          (5,128)Voyage expenses and commissions          (249,168)  (123,742)Vessel operating expenses          (252,956)  (175,473)Charter hire expenses          (3,974)  (1,620)Depreciation tangible assets          (216,568)  (162,767)Amortisation intangible assets          (1,428)  (1,602)Impairment reversals          729          (3,573)General and administrative expenses  (58,558)  (56,395)Total operating expenses  (783,926)  (530,300)       RESULT FROM OPERATING ACTIVITIES  871,573  216,498       Finance income  21,112  25,707Finance expenses  (178,981)  (208,147)Net finance expenses  (157,869)  (182,440)       Share of profit (loss) of equity accounted investees (net of income tax)          21,495  1,571       PROFIT (LOSS) BEFORE INCOME TAX  735,199  35,629       Income tax benefit (expense)  (1,985)  (2,840)       PROFIT (LOSS) FOR THE PERIOD  733,214  32,789       Attributable to:      Owners of the company  733,214  51,766Non-controlling interest  —          (18,977)       Basic earnings per share  2.53  0.27Diluted earnings per share  2.53  0.27       Weighted average number of shares (basic)  290,169,769  194,216,835Weighted average number of shares (diluted)  290,169,769  194,216,835                      Condensed consolidated interim statement of comprehensive income (unaudited)

(in thousands of USD)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025       Profit/(loss) for the period  733,214  32,789       Other comprehensive income (expense), net of tax      Items that will never be reclassified to profit or loss:      Remeasurements of the defined benefit liability (asset)          —          —       Items that are or may be reclassified to profit or loss:      Foreign currency translation differences  (4,356)  11,330Cash flow hedges - effective portion of changes in fair value  954  (1,794)       Other comprehensive income (expense), net of tax  (3,402)  9,536       Total comprehensive income (expense) for the period  729,812  42,325       Attributable to:      Owners of the company  729,812  61,302Non-controlling interest  —  (18,977)               Condensed consolidated interim statement of changes in equity (unaudited)

(In thousands of USD)

 Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2025239,148460,486(2,045)2,145(284,508)777,0981,192,324—1,192,324          Profit (loss) for the period        —        —        —        —        —51,76651,766(18,977)32,789Total other comprehensive income (expense)        —        —11,330(1,794)        —        —9,536—9,536Total comprehensive income (expense)        —        —11,330(1,794)        —51,76661,302(18,977)42,325          Transactions with owners of the company         Business Combination - Initial purchase        —        —        —        —        —        ——1,460,354        1,460,354Business Combination - Subsequent purchases        —        —        —        —        —        73,70573,705(210,771)(137,066)Dividends to Non-controlling interest        —        —        —        —        —        ——(5,095)(5,095)Total transactions with owners        —        —        —        —        —        73,70573,7051,244,4881,318,193          Balance at June 30, 2025239,148460,4869,285351(284,508)902,5691,327,3311,225,5112,552,842                               Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2026343,4401,817,5579,50290(284,508)737,2392,623,320—2,623,320          Profit (loss) for the period        —        —        —        —        —733,214733,214—733,214Total other comprehensive income (expense)        —        —(4,356)954        ——(3,402)—(3,402)Total comprehensive income (expense)        —        —(4,356)954        —733,214729,812—729,812          Transactions with owners of the company         Dividends to equity holders        —(127,675)        —        —        —(104,462)(232,137)—(232,137)Total transactions with owners—(127,675)———(104,462)(232,137)—(232,137)          Balance at June 30, 2026343,4401,689,8825,1461,044(284,508)1,365,9903,120,994—3,120,994                      Condensed consolidated interim statement of cash flows (unaudited)

(in thousands of USD)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025       Net cash from (used in) operating activities  417,287  73,098              Net cash from (used in) investing activities  (83,108)  (1,381,329)              Net cash from (used in) financing activities  (328,475)  1,424,516              Net increase (decrease) in cash and cash equivalents  5,704  116,285       Net cash and cash equivalents at the beginning of the period  146,529          38,869Effect of changes in exchange rates  (659)          (106)       Net cash and cash equivalents at the end of the period  151,574  155,048               1 Source: Clarksons SIN, NOAA, Citi, Ocean Analytics, Doric, Commodore Research
2 On 1 January 2026, the Baltic Exchange recalibrated its Capesize index by changing the standard reference vessel from a 180,000 DWT ship to a 182,000 DWT “eco” design. This update increased the baseline Baltic Capesize Index (BCI) time charter average by roughly USD 3,500 per day
3 Source: Clarksons SIN, IEA, Goldman Sachs, Bloomberg, CNBC, Citi, Vortexa
4 Announced vessels sales that have not yet been delivered to new owners are already excluded
5 Source: Clarksons
6 Source: Stolt Nielsen, Clarksons, S&P Global, SSY
7 Source: Clarksons

CMBT_Q2_2026_Earnings_release_ENG
2026-08-13 15:12 27d ago
2026-08-13 10:05 27d ago
Bio-Techne splnila odhady na EPS a tržby překonaly odhady
TECH Bio-Techne Corp
FMP Stock News 78
Original source text
Key Takeaways Bio-Techne's Q4 revenues rose 1% and topped estimates, while adjusted EPS met the consensus mark.TECH's Diagnostics and Spatial Biology organic revenues grew 8% from volume and profitability initiatives.Bio-Techne's Merck deal remains in focus, with the $73-per-share cash transaction progressing.
Bio-Techne Corporation (TECH - Free Report) reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, which dropped 1.9% year over year and came in line with the Zacks Consensus Estimate.

The quarter's adjustments eliminated the impact of certain items, including amortization of intangibles and Wilson Wolf intangible assets, acquisition-related expenses, certain litigation charges, stock-based compensation, restructuring and restructuring-related costs, and investment-related losses, among others.

GAAP EPS was 35 cents compared to a loss of 11 cents in the prior-year quarter.

For the full year, adjusted EPS of $1.93 increased 0.5% from the fiscal 2025 adjusted figure and surpassed the consensus mark by 1%.

TECH's Revenues in DetailIn the fiscal fourth quarter, net sales came in at $321.2 million, up 1% year over year on a reported basis and 3% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 1.26%. 

Full-year revenues were $1.22 billion, remaining flat from fiscal 2025 on both a reported and organic basis. Foreign currency had a favorable impact of 2%, while a business held for sale had an unfavorable impact of 2%. The metric came 0.8% above the consensus mark.

Following the announcement, TECH shares edged up 0.1% to close yesterday’s session at $72.23.

Segmental Analysis of TECH's Q4 RevenuesWithin Protein Sciences, Bio-Techne recorded revenues of $231.2 million, up 2% year over year from $226.5 million. Organic revenues increased 1%, while foreign currency had a favorable impact of 1%.

Within Diagnostics and Spatial Biology, revenues were $90.1 million, roughly flat from $89.7 million in the prior-year quarter. Organic revenues increased 8%, while the held-for-sale business had an unfavorable impact of 8%.

TECH’s Q4 MarginsBio-Techne’s gross profit increased 6.3% year over year to $211.4 million. The gross margin expanded 310 basis points (bps) to 65.8% as the cost of sales declined 7.1% to $109.8 million. Adjusted gross margin, however, contracted 80 basis points (bps) to 69.2%.

Selling, general and administrative expenses declined 42.4% to $113.2 million. Research and development expenses totaled $23.9 million, down 8.0% year over year. Total operating expenses fell 38.4% to $137.1 million from $222.7 million in the prior-year quarter.

The company generated operating income of $74.3 million in the fiscal fourth quarter compared to an operating loss of $23.9 million in the year-ago quarter.

Bio-Techne’s Capital StructureBio-Techne exited fiscal 2026 with cash and equivalents of $264.7 million compared with $162.2 million at the end of fiscal 2025. Long-term debt obligations totaled $200 million compared with $346 million at the end of the prior fiscal year.

Cumulative net cash provided by operating activities was $292.1 million at the end of fiscal 2026 compared with $287.6 million a year ago.

Bio-Techne’s Merck Deal Remains in FocusOn June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.

Management said it continues to make progress toward completing the transaction and expects the combination to create opportunities for the company’s customers and employees. In light of the announced deal, Bio-Techne is no longer holding investor conference calls for quarterly results.

Our Take on Bio-Techne’s ResultsBio-Techne exited the fourth quarter of fiscal 2026 with in-line earnings, while revenues surpassed estimates. Protein Sciences posted modest growth, supported by underlying organic gains, though unfavorable volume and product mix pressured segment profitability. Diagnostics and Spatial Biology delivered stronger organic growth and improved profitability, helped by favorable volume trends, ongoing profitability initiatives and the Exosome Diagnostics divestiture. Meanwhile, the contraction in adjusted gross margin during the quarter is discouraging.

TECH’s Zacks Rank & Key PicksBio-Techne currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks from the broader medical space are Labcorp Holdings (LH - Free Report) , Quest Diagnostics (DGX - Free Report) and Medpace (MEDP - Free Report) .

Labcorp, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $4.99, which surpassed the Zacks Consensus Estimate by 4.18%. Revenues of $3.73 billion beat the Zacks Consensus Estimate by 0.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

LH has an earnings yield of 5.9% compared with the industry’s 4.1% yield. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 3.09%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.
2026-08-12 12:43 28d ago
2026-08-12 06:30 28d ago
Bio-Techne schválila čtvrtletní dividendu 0,08 USD na akcii
TECH Bio-Techne Corp
FMP Stock News 78
Original source text
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio–Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer–focused brands: R&D Systems™, Bio–Techne Spatial™, and Bio–Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision–making. Bio–Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. 

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact: 

David Clair, Vice President, Investor Relations

[email protected]

612-656-4416

SOURCE Bio-Techne Corporation
2026-07-08 10:45 2mo ago
2026-07-08 06:30 2mo ago
Bio-Techne rozšířila portfolio proteinů pro buněčnou terapii
TECH Bio-Techne Corp
FMP Stock News 72
Original source text
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows

New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing , /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.  

By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes.

These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing.

Early adopters of R&D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications:

"Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion," said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies."

This real-world feedback underscores the broader potential of the R&D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows.

"As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical," said Will Geist, President of Bio-Techne's Protein Science Segment. "Our AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance—enabling more reproducible results and supporting seamless scale-up from discovery through production."

The newly launched proteins include:

FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.

For more information about the AI-Engineered Designer Protein portfolio, visit the R&D Systems website.

ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn and X.

MEDIA CONTACTS:
Corporate Communications
[email protected] 

David Clair, Vice President
Investor Relations
[email protected]

SOURCE Bio-Techne Corporation
2026-07-02 11:00 2mo ago
2026-07-02 05:31 2mo ago
Bio-Techne čelí prověření transakce s Merck
TECH Bio-Techne Corp
FMP Stock News 72
Original source text
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Bio-Techne shareholders will receive $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Bio-Techne by imposing a significant penalty if Bio-Techne accepts a competing bid. We are investigating the conduct of the Bio-Techne board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
2026-06-25 11:25 2mo ago
2026-06-25 06:09 2mo ago
Merck KGaA koupí Bio-Techne za 11,3 miliardy USD
TECH Bio-Techne Corp
FMP Stock News 92
Original source text
A cyclist drives past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 25 (Reuters) - German drugmaker Merck KGaA (MRCG.DE), opens new tab said on Thursday it will acquire U.S. biotech ​firm Bio-Techne Corp (TECH.O), opens new tab for $11.3 billion, expanding its presence ‌in the life sciences market.

Shares of Bio-Techne rose 22% in premarket trading following Merck's offer of $73 per share, which implies a 24% ​premium to Bio-Techne's close on Wednesday.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

With this deal, Merck ​will gain access to Bio-Techne's expertise and supplies ⁠of research reagents, proteins, antibodies, analytical instruments and other ​tools that are used by scientists and drug developers.

The deal ​follows a series of large healthcare transactions this year, including Danaher's (DHR.N), opens new tab $9.9 billion acquisition of patient-monitoring company Masimo in February, as medical technology and life ​sciences firms seek to broaden their product offerings and ​gain market share across multiple segments.

The Bio-Techne acquisition is Merck's largest life ‌sciences ⁠deal since its $17 billion takeover of Sigma-Aldrich in 2014, which bolstered the German group's laboratory supplies and research tools business and accelerated its diversification beyond pharmaceuticals.

The German firm said ​it would fund ​the Bio-Techne ⁠acquisition through a combination of cash and debt. The company has cash and cash equivalents ​of about 2.74 billion euros, according to its ​latest ⁠quarterly results.

The deal is expected to close by late 2026 or early 2027. Merck expects cost savings of about 140 ⁠million ​euros to be fully realized by ​the third year after the deal is closed.

Reporting by Danny Callaghan, Christy Santhosh ​and Padmanabhan Ananthan; Editing by Linda Pasquini and Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles., opens new tab